Presents a New Therapeutic Option for Patients with Recurrent Head and Neck Cancer Scheduled for Salvage Surgery

This Phase 2 clinical trial, NEOPOLIS (NRG-HN015, NCT07195734), is sponsored by the National Cancer Institute (NCI) and led by the NRG Oncology clinical research group. The trial is designed to evaluate patients with locally recurrent or persistent head and neck squamous cell carcinoma (HNSCC) who are PD-L1 positive and will undergo surgery, with the addition of chemotherapy or immunotherapy prior to surgery. This approach aims to address a patient population where salvage surgery alone has resulted in extremely high recurrence rates, representing an attempt to establish a new treatment pathway. A key objective is to reduce tumor size and suppress micrometastases through pre-operative systemic therapy.

Libtayo's Immunotherapy Synergy and Fusion of Diverse Drug Mechanisms

This study evaluates the efficacy of a three-drug combination therapy consisting of platinum-based chemotherapy (Paraplatin, active ingredient: carboplatin, DNA target) and microtubule-targeting agent (Taxol, active ingredient: paclitaxel, microtubule target) combined with Libtayo (active ingredient: cemiplimab, PD-1 target), a PD-1 targeting immune checkpoint inhibitor from Regeneron. This combination aims to maximize the anti-tumor effect by combining chemotherapy, which damages DNA and inhibits cell division, with immunotherapy, which activates T cells. Furthermore, a systematic multi-stage protocol is established to help eliminate residual cancer cells by adding platinum (Platinol, active ingredient: cisplatin, DNA target) and radiation therapy after surgery in high-risk patients.

Libtayo's Ambition to Expand Indications Amidst Intensifying Competition in the Immune Checkpoint Inhibitor Market

Currently, the head and neck cancer immunotherapy market is dominated by Merck's Keytruda (active ingredient: pembrolizumab, PD-1 target) and Bristol Myers Squibb's Opdivo (active ingredient: nivolumab, PD-1 target), which hold a monopoly as the standard of care (SoC). Regeneron aims to expand the approved indications for Libtayo, which has previously been approved for cutaneous squamous cell carcinoma (CSCC) and non-small cell lung cancer (NSCLC), to include head and neck squamous cell carcinoma (HNSCC) through this Phase 2 trial. If this trial yields significant data, such as improved survival rates, it could lead to direct competition for market share with existing market leaders.

Paradigm Shift and Re-evaluation Opportunity in the Rapidly Growing Head and Neck Cancer Market

The global head and neck cancer therapeutics market is currently valued at approximately $2 billion to $2.5 billion and is projected to grow rapidly to approximately $6.2 billion to $6.3 billion by 2033-2035. In the area of recurrent head and neck cancer, where there is still a high unmet medical need, if Libtayo demonstrates survival benefits, it could change the treatment paradigm. This is expected to significantly increase the value of Regeneron's pipeline and make a key contribution to the diversification of its long-term oncology portfolio.